<DOC>
	<DOCNO>NCT02336724</DOCNO>
	<brief_summary>Famitinib tyrosin-inhibitor agent target c-Kit , VEGFR2 , PDGFR , VEGFR3 , Flt1 Flt3 . Phase I study show toxicity manageable . The purpose study evaluate efficacy safety profile Famitinib patient advance metastatic gastrointestinal stromal tumor fail imatinib therapy .</brief_summary>
	<brief_title>A Study Famitinib Patients With Gastrointestinal Stromal Tumor</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>Unresectable advanced metastatic , histologicallyconfirmed , gastrointestinal stromal tumor.Patients fail last imatinib treatment due disease progression unacceptable toxicity unable use sunitinib . At least 2 week since last imatinib administration Must least one measurable disease RECIST1.1 criterion ( tumour lesion ≥10mm long diameter , malignant lymph node ≥15mm short axis , scan layer ≤ 5 mm ) . ECOG Performance status 01 Participants adequate organ marrow function define : neutrophil ≥ 1.5×10^9/L , platelets≥ 80×10^9/L , hemoglobin≥ 90g/L （no blood transfusion within 14 day ) , serum transaminase ( ALT AST ) ≤ 2.5×ULN ( If liver metastasis present , serum transaminase≤5×ULN ) , total bilirubin ≤ 1.25×ULN , cholesterol ≤ 7.75mmol/L triglyceride≤1 x ULN , creatinine ≤1x ULN , creatinine clearance rate &gt; 50ml/min Urine protein ≥ + + confirm 24hour urinary protein &gt; 1.0 g normal serum calcium , potassium , magnesium , phosphorus INR≤1.5 APTT≤1.5 ULN LVEF : ≥ 50 % Ability understand willingness sign write informed consent document . Prior therapy tyrosine kinase inhibitor agent target VEGFR , PDGFR cKit The toxicity previous imatinib treatment recover ≤ grade 1 accord CTCAE 3.0 Have surgery radiotherapy within 4 week temporary radiotherapy palliative treatment within 2 week A variety factor affect oral medication ( inability swallow , gastrointestinal resection , chronic diarrhea intestinal obstruction ) Other cancer diagnose within past 5 year currently suffer , cure basal cell carcinoma cervical carcinoma situ Within 12 month first treatment occur artery / venous thromboembolic event , cerebral vascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism , etc Uncontrollable thyroid dysfunction , even use medical therapy Preexisting arrhythmia ( include QT interval ≥ 450ms male 470ms female ) ≥ grade I heart failure Patients uncontrollable hypertension use single agent therapy ( systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg ) . Known acute chronic active hepatitis Immunodeficiency : HIV positive , acquire immunodeficiency , congenital immunodeficiency , organ transplantation Less 4 week last clinical trial Child bearing pregnancy female . Potential child bear female must negative urine serum pregnancy test result initiate . All subject surgically sterile postmenopausal must agree commit use reliable method birth control duration study 6 month last dose test drug . Evidence significant medical illness investigator 's judgment substantially increase risk associate subject 's participation completion study . Mental disorder history , Psychotropic drug abuse history Abuse Psychiatric drug dysphrenia Other reason investigator ' judgement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>gastrointestinal stromal tumor</keyword>
	<keyword>famitinib</keyword>
</DOC>